Jeff Jonas, president of Shire's ($SHPG) regenerative medicine division, said he's "optimistic, hopeful and enthusiastic" about prospects for the life sciences industry this year, and particularly his own business unit, which Shire created in 2011 after acquiring Advanced BioHealing. Part of that optimism stems from a focus on expanding the indications for Dermagraft--a skin substitute that obtained PMA from the FDA in 2001 to treat diabetic foot ulcers. Shire now wants to use Dermagraft to treat epidermolysis bullosa, a rare disease/skin defect where skin can become weak and fall off, leaving gaping wounds that require treatment. Shire just initiated a Phase III trial for this orphan disease indication in both the U.S. and Europe. Beyond Dermagraft, Jonas said Shire Regenerative Medicine "will be looking for early and late-stage opportunities beyond cell-based therapies" that aren't necessarily stem cell focused.